2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2519 Real-world practice patterns, safety, and efficacy of IDH1 inhibitor maintenance therapy following allogeneic hematopoietic cell transplantation

Alexander Joseph Ambinder, MD, MPH, Kuo-Kai Chin, M.D.2, Michael Walker3, Deedra Nicolet, MS4, Krzysztof Mrózek, MD, PhD5, Haley Roberts6, Thomas Kehoe7, Utsav Joshi, MD8, Abdur Jabir9, Yamuna Kondapally, MD10, Evan Greeson11, Abhay Singh, MD, MPH12, Jennifer Marvin-Peek, MD13, Yazan F. Madanat, MD14, Akriti G Jain, MD, FACP15, David Swoboda, MD16, Onyee Chan, MD17, Madelyn Burkart, MD18, Praneeth Baratam, MBBS19, Daniel Pollyea, MD20, B. Douglas Smith, MD21, Ann-Kathrin Eisfeld, MD22, Vanessa E Kennedy, MD23
1 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 University of South Florida, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 University of Illinois College of Medicine, Chicago, United States
10 Stanford Cancer Center, Stanford, California, United States
11 Medical University of South Carolina, Charleston, United States
12 Cleveland Clinic Cancer Center, Cleveland, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 UT Southwestern Cancer Center, Dallas, Texas, United States
15 Cleveland Clinic Cancer Center, Cleveland, United States
16 Tampa General Hospital Cancer Institute, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
19 Medical University of South Carolina, Charleston, United States
20 University of Colorado, Denver, Colorado, United States
21 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
22 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
23 Stanford Cancer Center, Stanford, California, United States

Introduction: Patients with AML at high risk of relapse routinely undergo consolidative allogeneic hematopoietic cell transplant (alloHCT). Various post-transplant maintenance therapies have been studied to further reduce relapse, but for most, there is little high-quality evidence to support their use as standard of care. Ivosidenib, an IDH1 inhibitor (IDH1i), has previously been found to be safe to administer as post-transplant maintenance in a small prospective phase 1 study, but outcomes have not been compared to a control arm. We aimed to characterize the real-world use of IDH1i as post-transplant maintenance and to assess its safety and association with post-transplant outcomes.

Methods: This multicenter retrospective study included patients with IDH1-mutated AML who underwent consolidative alloHCT at 11 US centers in the MARROW Consortium (Myeloid Malignancy Association on Rapid Research Outcomes Working Group). Eligible patients survived to day +60 post-transplant and had documented data on post-transplant IDH1i maintenance, defined as IDH1i initiation within one year of alloHCT without evidence of relapse; Patients receiving post-transplant gilteritinib were excluded. We characterized baseline patient, disease, and transplant characteristics, and the dose and duration of IDH1i use. Using a day-60 landmark analysis, we compared overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse and non-relapse mortality (NRM), and GVHD between patients who did and did not receive IDH1i. Baseline and relapse co-mutational profiles were also compared between groups.

Results: Of 278 patients, 208 survived to the day-60 landmark with available maintenance data;16 of the 70 patients excluded died before day 60. Of the 208 included patients, 40 (19%) received IDH1i maintenance and 168 (81%) did not. Median age was 62 years, 50% received intensive chemotherapy, 23% received a pre-alloHCT IDH1i, 59% had an HCT-CI ≤ 2, 98% were transplanted in composite CR (CR, CRh, or CRi), and 65% received reduced-intensity conditioning. Overall groups were balanced except that maintenance patients more often received PTCy-based prophylaxis (85% vs 64%, P=0.02). Among the 79% of patients who underwent pre-alloHCT molecular testing, maintenance and non-maintenance had similar rates of detectable pre-HCT IDH1 mutation (62% vs 47%, P=0.21), and pre-transplant MRD by multiparametric flow cytometry (17% vs 26%, P=0.38). Median time to maintenance start was 2.9 months (range 0 – 11.9) and the median duration was 12.0 months (range 0.7 – 113.8). Severe (grade III–IV) acute GVHD was uncommon and similar between groups (3% and 4%, P=0.44). Maintenance was not associated with improved outcomes: cumulative incidence of relapse (Gray's P=0.80), NRM (P=0.42), RFS (HR 0.88, 95%CI 0.43-1.79), and OS (HR 0.48, 95% CI 0.17-1.34) did not differ. Two-year estimates were similar: cumulative incidence of relapse 4% vs 6%, RFS 80% vs 74%, and OS 90% vs 83%. The IDH1 mutation was retained at relapse in 76% of patients and did not differ by maintenance status, nor in relapse co-mutational profiles.

Conclusion: In this multicenter retrospective analysis, off-label IDH1i maintenance was used in 19% of patients, with variation across centers. Maintenance appeared safe but was not associated with clear improvements in post-transplant outcomes. This finding should be interpreted cautiously given the retrospective design and potential for unmeasured confounding, although baseline characteristics were similar between groups. Patients with IDH1-mutated AML undergoing alloHCT also had excellent post-transplant outcomes, making an incremental benefit difficult to demonstrate given a limited sample size. To our knowledge, this is the first comparative study to evaluate the impact of post-transplant IDH1i maintenance on transplant outcomes. These findings can help inform the selective use of off-label IDH1i maintenance in current practice. Larger collaborative analyses with extended follow-up, and studies incorporating novel approaches to MRD assessment, may further clarify which patients are most likely to benefit.

Alexander Joseph Ambinder, MD, MPH: Servier - Consultancy (Includes expert testimony); J&J - Consultancy (Includes expert testimony)